摘要
氩氦刀1998年通过美国FDA批准和IEC及EMC认证,目前已被世界500多所医院用于肿瘤治疗。我国自1999年引进氩氦刀以来,已有2万多肿瘤患者接受氩氦靶向消融术治疗,有效率达90%以上。临床证实,氩氦靶向治疗技术可以有效地治疗肺癌、肝癌、脑肿瘤、乳腺等实体肿瘤。与化疗、放疗、生物治疗及中医药结合治疗可取得满意的临床效果。
Cryocare Surgical System is a new targeted cryoablation therapy for tumor treatment. It had psssed permission by FDA,IEC,EMC before 1998 year and has been used by .500 hospitals in the world. Since 1999 year, about 20000 cases d cancer patients have been treated by cryocare targeted cryoablation therapy in China. Cryocare Surgical System was confirmed to be an usefully targeted treatment technology for lung cancer,liver cancer,brain tumor,breast tumor, and other tumors. It also can be used on clinical oncology treatment combining with chemotherapy、radiotherapy、immunotherapy and Chinese traditional therapy together.
出处
《生物医学工程研究》
2005年第2期128-132,共5页
Journal Of Biomedical Engineering Research
关键词
美国氩氮刀
靶向治疗
肿瘤
Endocare Cryocare Surgical System
Targeted crymblation therapy
Tumor
